ArticleACS omega2025
LC and LC-MS/MS Analysis for Characterization of Novel Degradation Products of Ivosidenib: Exploration of Degradation Pathways and In Silico Predictions.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Construction of CFBeilstein journal of organic chemistry · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Ivosidenib (ISB) is an anticancer drug used to treat acute myeloid leukemia and cholangiocarcinoma. In order to determine and describe the degradation products (DPs) of ivosidenib, the International Conference on Harmonization (ICH) guidelines (Q1A, R2) suggest conducting stress degradation studies by subjecting the drug to acidic, alkaline, neutral hydrolysis, thermal, photolytic, and oxidative conditions. These studies are crucial for understanding the stability of the drug and ensuring its safe use. Liquid chromatography (LC) and LC-MS/MS are essential for identifying and characterizing these DPs. Ivosidenib is sensitive to degradation under acidic, alkaline, photolytic, and oxidative conditions at room temperature but is stable under neutral hydrolysis and thermal conditions. The separation of ISB and its four DPs was achieved using a Waters Acquity UPLC BEH C-18 column, with gradient elution comprising 0.1% trifluoroacetic acid (TFA) as mobile phase-A and acetonitrile as mobile phase-B. The detection was carried out at a wavelength of 215 nm with a flow rate of 0.3 mL/min and a 5 μL injection volume. The LOQ was 0.05%, and the LOD was 0.02% of the nominal concentration. Four DPs were identified, with DP-I predominant under acidic and alkaline conditions and DP-II under basic and oxidative conditions. Oxidative and photolytic conditions produced DP-III and DP-IV respectively. A novel HRMS-MS/TOF method was developed to identify and characterize these DPs, with each analyzed in an ESI-positive mode. Finally, Glide software was used to predict docking scores, while TOPKAT software was used to evaluate the in silico toxicity of ISB and its DPs. The in silico findings revealed that DP-III is the most active and is the least toxic.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.